Adjunctive taurine in first-episode psychosis: A phase 2, double-blind, randomized, placebo-controlled study

Journal of Clinical Psychiatry

Volumn 77, Issue 12, 2016, Pages e1610-e1617

  O'Donnell, Colin P ^a   Allott, Kelly A ^d,e   Murphy, Brendan P ^b,c   Yuen, Hok Pan ^d,e   Proffitt, Tina Marie ^d,e   Papas, Alicia ^d   Moral, Jennifer ^d   Pham, Tee ^d   O'Regan, Michaela K ^d   Phassouliotis, Christina ^d   Simpson, Raelene ^d   McGorry, Patrick D ^d,e  

^a Donegal Mental Health Service   (Ireland)

^b Early in Life Mental Health Service   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TAURINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CALGARY DEPRESSION SCALE; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; YOUNG ADULT; ADOLESCENT; CLINICAL TRIAL; COGNITIVE DYSFUNCTION; COMBINATION DRUG THERAPY; COMPLICATION; EARLY INTERVENTION; MULTICENTER STUDY; OUTCOME ASSESSMENT; PSYCHOTIC DISORDERS;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; COGNITIVE DYSFUNCTION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTIC DISORDERS; TAURINE; YOUNG ADULT;

EID: 85007557441     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15m10185     Document Type: Article

References (52)

1. Gallego JA, Robinson DG, Sevy SM, et al. Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months? J Clin Psychiatry. 2011;72(12):1691-1696. doi:10.4088/JCP.10m06349
2. Ventura J, Subotnik KL, Gitlin MJ, et al. Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later. Schizophr Res. 2015;161(2-3):407-413. doi:10.1016/j.schres.2014.10.043
3. Mesholam-Gately RI, Giuliano AJ, Goff KP, et al. Neurocognition in first-episode schizophrenia: A meta-Analytic review. Neuropsychology. 2009;23(3):315-336. doi:10.1037/a014708
4. Huxtable RJ. Physiological actions of taurine. Physiol Rev. 1992;72(1):101-163.
5. Lourenço R, Camilo ME. Taurine: A conditionally essential amino acid in humans? an overview in health and disease. Nutr Hosp. 2002;17(6):262-270.
6. Ikeda H. Effects of taurine on alcohol withdrawal. Lancet. 1977;2(8036):509. doi:10.1016/S0140-6736(7)91636-1
7. Shirayama Y, Obata T, Matsuzawa D, et al. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: A preliminary study. Neuroimage. 2010;49(3):2783-2790. doi:10.1016/j.neuroimage.209.10.031
8. Do KQ, Lauer CJ, Schreiber W, et al. gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem. 1995;65(6):2652-2662. doi:10.1046/j.1471-4159.195.65062652.x
9. Engelborghs S, Marescau B, De Deyn PP. Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinsons disease. Neurochem Res. 2003;28(8):1145-1150. doi:10.1023/A:102425208563
10. First M, Spitzer R, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 2001.
11. Takahashi R, Nakane Y. Clinical trial of taurine in epilepsy. In: Barbeau A, Huxtable RJ, eds. Taurine and Neurological Disease. New York, NY: Raven Press; 1978:375-385.
12. Mantovani J, DeVivo DC. Effects of taurine on seizures and growth hormone release in epileptic patients. Arch Neurol. 1979;36(11):672-674. doi:10.101/archneur.1979.0504704206
13. Fukuyama Y, Ochiai Y. Therapeutic trial by taurine for intractable childhood epilepsies. Brain Dev. 1982;4(1):63-69. doi:10.1016/S0387-7604(82)80103-4
14. Bergamini L, Mutani R, Delsedime M, et al. First clinical experience on the antiepileptic action of taurine. Eur Neurol. 1974;11(5):261-269. doi:10.159/014324
15. Azuma J, Takihara K, Awata N, et al. Taurine and failing heart: experimental and clinical aspects. Prog Clin Biol Res 1985;179:195-213. doi:
16. Fujita T, Katsuyuki A, Noda H, et al. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation. 1987;75:525-32. doi:
17. Hardison WGM, Grundy SM. Effect of bile acid conjugation pattern on bile acid metabolism in normal humans. Gastroenterology. 1983;84(3):617-620.
18. Mizushima S, Nara Y, Sawamura M, et al. Effects of oral taurine supplementation on lipids and sympathetic nerve tone. Adv Exp Med Biol. 1996;403:615-622. doi:10.107/978-1-489-0182-868
19. Azuma J, Sawamura A, Awata N, et al. Doubleblind randomized crossover trial of taurine in congestive heart failure. Curr Ther Res. 1983;34:543-557.
20. Verberk WJ, Kroon AA, Kessels AG, et al. Comparison of randomization techniques for clinical trials with data from the HOMERUStrial. Blood Press. 2005;14(5):306-314. doi:10.1080/080370505031538
21. Treasure T, MacRae KD. Minimisation: The platinum standard for trials? randomisation doesnt guarantee similarity of groups; minimisation does. BMJ. 1998;317(7155):362-363. doi:10.136/bmj.317.715.362
22. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31(1):103-115. doi:10.2307/2529712
23. Early Psychosis Guidelines Writing Group. Australian Clinical Guidelines for Early Psychosis. 2nd ed. Melbourne, Australia: Orygen Youth Health; 2010.
24. Nelson HE, Willison J. National Adult Reading Test (NART): Test Manual. 2nd ed. Windsor, UK: NFER Nelson; 1991.
25. Ventura J, Lukoff D, Nuechterlein KH, et al. Brief Psychiatric Rating Scale (BPRS) Expanded Version (4.0). Scales, Anchor Points, and Administration Manual. West Los Angeles, CA: UCLA Department of Psychiatry and Behavioral Sciences; 1993.
26. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. doi:10.1093/schbul/13.2.261
27. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa; 1984.
28. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3(4):247-251. doi:10.1016/0920-964(90)905-R
29. Haro JM, Kamath SA, Ochoa S, et al; SOHO Study Group. The Clinical Global Impression-Schizophrenia scale: A simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand suppl. 2003;107(416):16-23. doi:10.1034/j.160-047.107.s416.5.x
30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-IV-TR). 4th ed. Washington, DC: American Psychiatric Association; 2000.
31. Nuechterlein KH, Green MF. MATRICS Consensus Cognitive Battery (MCCB). Los Angeles, CA: MATRICS Assessment Inc.; 2006.
32. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-Treated patients. Acta Psychiatr Scand suppl. 1987;334:1-100. doi:10.1/j.160-047.1987.tb1056.x
33. Little R, Rubin D. Statistical Analysis With Missing Data. New York: Wiley and Sons; 1987.
34. Schafer J. Analysis of Incomplete Multivariate Data. London, UK: Chapman and Hall; 1997. doi:10.1201/9781439821862
35. Dempster A, Laird N, Rubin D. Maximum likelihood estimation from incomplete data via the EM algorithm. J Royal Stat Soc. 1977;39(1):1-38.
36. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.
37. Thalheimer W, Cook S. How to calculate effect sizes from published research articles: A simplified methodology. http://www. bwgriffin.com/gsu/courses/edur9131/content/Effect-Sizes-pdf5.pdf. 2002. Accessed August 9, 2012.
38. Gardner DM, Murphy AL, ODonnell H, et al. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167(6):686-693. doi:10.176/api.ajp.209.09060802
39. Wesseling H, Chan MK, Tsang TM, et al. A combined metabonomic and proteomic approach identifies frontal cortex changes in a chronic phencyclidine rat model in relation to human schizophrenia brain pathology. Neuropsychopharmacology. 2013;38(12):2532-2544. doi:10.1038/np.2013.160
40. Vermeiren Y, Le Bastard N, Van Hemelrijck A, et al. Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia. Alzheimers Dement. 2013;9(5):488-498. doi:10.1016/j.jalz.2012.06.010
41. Altamura C, Maes M, Dai J, et al. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol. 1995;5(suppl):71-75. doi:10.1016/0924-97X(95)03-L
42. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
43. Mitani H, Shirayama Y, Yamada T, et al. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1155-1158. doi:10.1016/j.pnpbp.206.03.036
44. Maes M, Verkerk R, Vandoolaeghe E, et al. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand. 1998;97(4):302-308. doi:10.1/j.160-047.198.tb104.x
45. Caletti G, Olguins DB, Pedrollo EF, et al. Antidepressant effect of taurine in diabetic rats. Amino Acids. 2012;43(4):1525-1533. doi:10.107/s0726-012-126-x
46. Toyoda A, Iio W. Antidepressant-like effect of chronic taurine administration and its hippocampal signal transduction in rats. Adv Exp Med Biol. 2013;775:29-43. doi:10.107/978-1-4614-6130-23
47. Hernández-Benítez R, Pasantes-Morales H, Saldaña IT, et al. Taurine stimulates proliferation of mice embryonic cultured neural progenitor cells. J Neurosci Res. 2010;88(8):1673-1681.
48. Palackal T, Moretz R, Wisniewski H, et al. Abnormal visual cortex development in the kitten associated with maternal dietary taurine deprivation. J Neurosci Res. 1986;15(2):223-239. doi:10.102/jnr.490150212
49. Maar T, Morán J, Schousboe A, et al. Taurine deficiency in dissociated mouse cerebellar cultures affects neuronal migration. Int J Dev Neurosci. 1995;13(5):491-502. doi:10.1016/0736-5748(95)068-R
50. Tyson JE, Lasky R, Flood D, et al. Randomized trial of taurine supplementation for infants less than or equal to 1, 300-gram birth weight: effect on auditory brainstem-evoked responses. Pediatrics. 1989;83(3):406-415.
51. Kroken RA, Løberg E-M, Drønen T, et al. A critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammation. Front Psychiatry. 2014;5(11):11.
52. Jia F, Yue M, Chandra D, et al. Taurine is a potent activator of extrasynaptic GABA(A) receptors in the thalamus. J Neurosci. 2008;28(1):106-115. doi:10.1523/JNEUROSCI.396-07.208